The type 1 form of 17b-hydroxysteroid dehydrogenase (17bHSD1) was the first isoform to be identified and is capable of converting estrone to 17b-estradiol. This study was aimed at characterizing the molecular structure of the equine 17bHSD1 gene and cDNA, as well as its molecular regulation during human chorionic gonadotropin (hCG)-induced follicular luteinization/ovulation in vivo. The equine 17bHSD1 gene was cloned from an equine genomic library and shown to have a conserved genomic structure composed of six exons. Its cDNA sequence was also identified and coded for a 308 amino acid protein, 72 . . 5% homologous to other mammalian orthologs. RT-PCR/Southern blot analyses were performed to study the regulation of the 17bHSD1 transcript in equine preovulatory follicles isolated between 0 and 39 h after hCG treatment. Results demonstrated the presence of high 17bHSD1 mRNA expression prior to hCG treatment with a marked decrease observed 12 h after hCG (P!0 . 05). Analyses on isolated preparations of granulosa and theca interna cells identified the granulosa cell layer as the site of 17bHSD1 transcript expression and downregulation (P!0 . 05). A 1412 bp fragment of the equine 17bHSD1 proximal promoter was sequenced and shown to contain many putative transcription factor binding sites. Electromobility shift assays (EMSA) using a fragment of the proximal promoter (K230/K30) and nuclear extracts prepared from granulosa cells isolated prior to hCG (0 h post-hCG) revealed the presence of a major complex, and results from competition assays suggest that steroidogenic factor-1 (SF-1), NFkB, GATA, and Sp1 cis-elements are involved. Supershift assays using an antibody against the p65 subunit of NFkB led to the displacement of the binding nuclear proteins to the DNA probe, whereas the use of an anti-equine SF-1 antibody demonstrated the clear formation of a DNA-protein-antibody complex, confirming the potential role of these transcription factors in EMSA results. Interestingly, a notable decrease in DNA binding was observed when granulosa cell nuclear extracts isolated 30 h post-hCG were used, which paralleled the decrease in 17bHSD1 transcript after hCG treatment. Thus, this study is the first to report the gonadotropin-dependent downregulation of 17bHSD1 transcript expression in a monoovulatory species, the presence and regulation of protein/DNA interactions in the proximal region of the 17bHSD1 promoter during gonadotropin treatment, and the characterization of the primary structure of equine 17bHSD1 cDNA and gene.
Introduction
The biosynthesis of ovarian steroid hormones requires a complex enzymatic cascade that ultimately involves the enzyme, 17b-hydroxysteroid dehydrogenase (17bHSD), in the production of both androgen and estrogen secretory products. Twelve types of 17bHSDs have thus far been described, and numbered in the order in which their DNA sequences were determined. They are all members of the short-chain dehydrogenase/reductase superfamily, except for type 5, which belongs to the aldo-keto reductase superfamily (Adamski & Jakob 2001 , Baker 2001 , Luu-The 2001 , Luu-The et al. 2005 . These 17bHSDs catalyze the interconversion between less active 17-ketosteroids (i.e. low receptor affinity) and more active 17b-hydroxysteroids (i.e. high receptor affinity) such as estrone and 17b-estradiol respectively (Penning 1997 , Peltoketo et al. 1999 . The occurrence of different substrate specificities, cofactor preference, subcellular localizations, and tissue distributions allows 17bHSDs to dictate the biological potency of androgens and estrogens in mammals.
Type 1 17bHSD (17bHSD1) was the first 17bHSD to be characterized. Its cDNA was first cloned from human placenta and was shown to encode a cytosolic protein of 327 amino acids (Peltoketo et al. 1988 , Luu The et al. 1989 . It has been shown to preferentially catalyze the reduction of estrone to 17b-estradiol using NADP(H) as a cofactor in humans (Dumont et al. 1992 , Lin et al. 1992 , whereas its substrate specificity in rodents is broader as it includes androstenedione (Nokelainen et al. 1996 , Mustonen et al. 1997 . Tissue distribution analyses revealed 17bHSD1 transcript expression in the ovary, placenta, breast, endometrium, prostate, skin, and adipose tissue (Peltoketo et al. 1988 , Dumont et al. 1992 .
In mammals, the preovulatory surge in luteinizing hormone is responsible for the process of follicular luteinization, which is accompanied by dramatic changes in follicular steroidogenesis, including the decreased biosynthesis of 17b-estradiol (Fortune 1994 , Zeleznik 1994 , Murphy 2000 . The marked decrease in expression of cytochrome P450 enzymes, such as P450 aromatase (CYP19A1) and P450 17a-hydroxylase/C17-20 lyase (CYP17A1), has been used to explain this loss in 17b-estradiol biosynthetic capacity (Fortune 1994 , Richards 1994 , Liu et al. 1999 . To date, no attempts have been made to elucidate the regulation of enzymes required for the activation of these estrogens, such as 17bHSD1, during the luteinization process in monoovulatory species. The present study uses the equine preovulatory follicle as a model to investigate the regulation of 17bHSD1 during gonadotropin-induced ovulation/luteinization. The specific objectives were to clone the equine 17bHSD1 gene and cDNA, and determine the regulation of its mRNA in preovulatory follicles following human chorionic gonadotropin (hCG) treatment, as well as begin characterizing interactions at the level of the 17bHSD1 promoter.
Materials and methods

Materials
The QuickHyb hybridization solution and the equine genomic library were obtained from Stratagene Cloning Systems (LaJolla, CA, USA); [a- 32 P]dCTP was purchased from Perkin-Elmer Canada, Inc. (Woodbridge, Ontario, Canada) ; the Prime-a-Gene labeling system and pGEM-T Easy Vector System I were obtained from Promega Corp.; the Expand High Fidelity DNA polymerase was purchased from Roche Diagnostics (Laval, Québec, Canada); the plasmid pcDNA3 . 1, SuperScript II reverse transcriptase, TRIzol total RNA isolation reagent, 1 kb DNA ladder, 5 0 -rapid amplification of cDNA ends (RACE) system (version 2.0), and synthetic oligonucleotides were obtained from Invitrogen Life Technologies; the Qiagen OneStep RT-PCR System was purchased from Qiagen, Inc.; Biotrans nylon membranes (0 . 2 mm) were obtained from ICN Pharmaceuticals, Inc. (Montréal, Québec, Canada); Bio-Rad Protein Assay and all electrophoretic reagents were obtained from Bio-Rad Laboratories; hCG was purchased from The Butler Co. (Columbus, OH, USA); and poly (dI/dC) was obtained from Amersham Pharmacia Biotech. Polyclonal antibodies against p65 nuclear factor (NF)kB (catalog number sc-372X), p50 NFkB (sc-7178X), and GATA-4 (sc-9053x) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The equine-specific SF-1 protein was produced by the Sheldon Biotechnology Center, McGill University (Montreal, PQ, Canada).
Characterization of the equine 17bHSD1 cDNA and gene
The equine 17bHSD1 cDNA was characterized by a combination of 5 0 -rapid amplification of cDNA ends (5 0 -RACE) and genomic cloning. A cDNA fragment was first isolated by RT-PCR using sense primer 1 and antisense primer 2 designed by sequence alignments of 17bHSD1 homologs from other species, 100 ng RNA obtained from a preovulatory follicle isolated prior to hCG administration (0 h; see below), and the Qiagen OneStep RT-PCR System as directed by the manufacturer (Fig. 1A ; RT-PCR1). As a second approach, the 5 0 end of equine 17bHSD1 was characterized using the 5 0 -RACE system version 2.0 (Invitrogen Life Technologies) according to the manufacturer's instructions. Reverse transcription was performed using anti-sense primer 3 ( Fig. 1A ; 5 0 -RACE) and 3 mg RNA from a preovulatory follicle isolated prior to hCG administration. The first 5 0 -RACE/PCR was accomplished with sense abridged anchor primer 4 (Invitrogen Life Technologies) and antisense primer 5, whereas the second 5 0 -RACE/PCR employed the sense abridged universal amplification primer 6 (Invitrogen Life Technologies) and anti-sense primer 7 ( Fig. 1A; 5 0 -RACE). PCRs consisted of 35 cycles of 94 8C for 30 s, 56 8C for 1 min, and 72 8C for 1 min.
RT-PCR and 5
0 -RACE cDNA products were subcloned into the pGEM-T Easy plasmid vector (Promega), and sequenced by the Service de Séquençage de l'Université Laval (Québec, Canada).
Despite numerous attempts to clone the remaining 3 0 end of the open reading frame, they remained unsuccessful. As a second approach, an equine genomic library (Stratagene) was screened with the equine RT-PCR 17bHSD1 cDNA fragment, as previously described (Liu et al. 1999) . The probe was labeled with [a-32 P]dCTP using the Prime-a-Gene labeling system (Promega) to a final specific activity greater than 1!10 8 c.p.m./mg DNA, and hybridization was performed at 68 8C with QuickHyb hybridization solution (Stratagene). Positive clones were plaque purified through secondary and tertiary screenings, and DNA sequencing was performed commercially as described earlier. The equine 17bHSD1 genomic sequence was used to design an oligonucleotide 3 0 to the coding region. This primer, as well as another oligonucleotide designed from the 5 0 end of the cDNA (primers 8 and 9; Fig. 1A ; 5 0 -RACE), allowed RT-PCR amplification of the complete open reading frame, thereby confirming the contiguous cDNA sequence presented herein ( Fig. 1A; RT-PCR2). The complete equine genomic sequence was obtained after a number of sequencing reactions using equine 17bHSD1-specific primers. A comparison of the cDNA and the resulting genomic DNA sequences was used to determine the gene structure of equine 17bHSD1 as well as the exon-intron junctions (Fig. 2) .
Equine tissues
Equine preovulatory follicles and corpora lutea were isolated at specific stages of the estrous cycle from Standardbred and Thoroughbred mares, 3-10 years old and weighing approximately 375-450 kg, as previously described (Sirois & Doré 1997) . Briefly, when preovulatory follicles reached 35 mm in diameter during estrus, the ovulatory process was initiated by injection of hCG (2500 IU, i.v.) . Ovariectomies were then performed via colpotomy using an ovariotome at 0, 12, 24, 30, 33, 36, or 39 h post-hCG (nZ4-6 mares/time point). Follicles were dissected into preparations of follicle wall (theca interna with attached granulosa cells) or further dissected into separate isolates of granulosa cells and theca interna, as previously described (Sirois et al. 1991) . Ovariectomies were also performed on day 8 of the estrous cycle (day 0Z day of ovulation) to obtain corpora lutea (nZ3 mares). Testicular tissues were obtained from the Large Animal Hospital of the Faculté de Médecine Vétérinaire (Université de Montréal) following a routine castration, whereas other nonovarian tissues were collected at a local slaughterhouse. All animal procedures were approved by the Institutional Animal Use and Care Committee.
RNA extraction and semi-quantitative RT-PCR/Southern analysis
Total RNA was isolated from tissues with TRIzol reagent (Invitrogen Canada, Inc.), according to manufacturer's instructions using a Kinematica PT 1200C Polytron Homogenizer (Fisher Scientific, Montréal, Canada). The OneStep RT-PCR System (Qiagen) was used for semi-quantitative analysis of 17bHSD1 and rpL7a mRNA levels (control gene) in equine tissues. Reactions were performed as directed by the manufacturer, using sense (5 0 -ACCTTGCAGTTGGACGTGAGAGA-3 0 ) and antisense (5 0 -TCGCGGTACATCTGCTCGCAGT-3 0 ) primers specific for equine 17bHSD1. Sense (5 0 -ACAGGACATC-CAGCCCAAACG-3 0 ) and anti-sense (5 0 -GCTCCTTTGT-CTTCCGAGTTG-3 0 ) primers specific for equine rpL7a were designed from a published sequence deposited in GenBank (Accession no. AF508309). These reactions resulted in the production of 17bHSD1 and rpL7a DNA fragments of 503 and 516 bp respectively. Each reaction was performed using 100 ng total RNA, and cycling conditions were one cycle of 50 8C for 30 min and 95 8C for 15 min, followed by a variable number of cycles of 94 8C for 1 min, 60 8C for 1 min, and 72 8C for 1 min. The number of cycles used was optimized for each gene to fall within the linear range of PCR amplification, and were 26 and 18 cycles for 17bHSD1 and rpL7a respectively. Following PCR amplification, samples were subjected to electrophoresis on 2% tris-acetate EDTA (TAE)-agarose gels, transferred to nylon membranes, and hybridized with corresponding radiolabeled 17bHSD1 and rpL7A cDNA fragments using QuikHyb hybridization solution (Stratagene). Membranes were exposed to a phosphor screen, and signals were quantified by means of a Storm imaging system using the ImageQuant software version 1.1 (Molecular Dynamics, Amersham Biosciences).
Granulosa cell nuclear extracts and electrophoretic mobility shift assays (EMSAs)
Equine granulosa cells were obtained from preovulatory follicles isolated at 0 and 30 h post-hCG and nuclear extracts were prepared as described (Sirois et al. 1993 , Liu et al. 1999 . Protein concentration in each extract was determined by the method of Bradford (1976) . EMSAs were performed as described (Sirois et al. 1993 , Liu et al. 1999 , with minor modifications.
Briefly, extracts of nuclear proteins (0 . 5 mg/reaction) were incubated with 40 000 c.p.m. of end-labeled K230/K30 17bHSD1 promoter fragment and 1 mg poly(dI/dC) (Amersham Biosciences) in a final volume of 20 ml binding buffer containing 15 mM Tris-HCl (pH 7 . 5), 1 mM EDTA, 100 mM KCl, 5 mM MgCl 2 , 5 mM dithiothreitol, and 12% (v/v) glycerol. Cold oligonucleotide pairs, both wild type and mutated, were used in 50 times molar excess in order to determine the identity of bound sequence. When antibodies (Santa Cruz Biotechnology) were used in supershift EMSAs, the nuclear extract was first incubated for 1 h on ice with the antiserum prior to the addition of other reagents. Binding complexes were resolved by 5% acrylamide, 0 . 5! tris-borate EDTA (TBE) gel electrophoresis.
Protein extracts, anti-equine SF-1 antibody, and immunoblot analysis
Preovulatory follicle extracts were prepared as previously described (Filion et al. 2001) . Briefly, tissue was homogenized and sonicated on ice in TED buffer (20 mm Tris (pH 8 . 0), 50 mm EDTA, and 0 . 1 mm diethyldithiocarbamic acid) containing 1 . 0% Tween.
The sonicate was centrifuged at 16 000 g for 15 min at 4 8C. The recovered supernatant (whole cell extract) was stored at K80 8C until electrophoretic analyses were performed. Protein concentration was determined by the method of Bradford (1976; Bio-Rad protein assay) . Samples (50 mg proteins) were resolved by one-dimensional SDS-PAGE and electrophoretically transferred to polyvinylidene difluoride membranes (Filion et al. 2001) . The equine-specific anti-SF-1 polyclonal antibody was generated as previously described (Brown et al. 2004 ) using a peptide fragment encompassing amino acids Cys 248 to Ser 262 (Sheldon Biotechnology Center). Membranes were incubated with the polyclonal antiequine SF-1 antibody (1:1000) and immunoreactive proteins were visualized on Kodak X-OMAT AR film (Eastman Kodak Co., Rochester, NY, USA) after incubation with the horseradish peroxidase-linked donkey anti-rabbit secondary antibody (1:10 000 dilution) and the enhanced chemiluminescence system (ECL Plus), following the manufacturer's protocol (Amersham Pharmacia Biotech).
Statistical analysis
One-way ANOVA was used to test the effect of time after hCG administration on levels of 17bHSD1 mRNA in samples of follicle wall, corpora lutea, theca interna, and granulosa cells. 17bHSD1 transcript levels were normalized with the control gene rpL7a before analysis. When ANOVAs indicated significant differences (P!0 . 05), Dunnett's test was used for multiple comparisons of individual means. Statistical analyses were performed using JMP software (SAS Institute, Inc., Cary, NC, USA).
Results
Characterization of the equine 17bHSD1 cDNA, gene, and protein
To clone the equine 17bHSD1 transcript, RT-PCR was performed on ovarian RNA using oligonucleotide primers designed by sequence alignment of 17bHSD1 homologs in other species. The resulting cDNA fragment ( Fig. 1A ; RT-PCR1) was sequenced and found to be highly homologous to 17bHSD1 transcripts identified thus far. The 5 0 -RACE reactions yielded a cDNA product corresponding to the remaining 5 0 end coding regions, as well as the 5 0 -untranslated region ( Fig. 1A; 5 0 -RACE). An equine genomic library was screened with a cDNA probe obtained by RT-PCR. The genomic sequence of equine 17bHSD1 was determined by performing several sequencing reactions (GenBank Accession number DQ418450) and used to derive the 3 0 end of the equine 17bHSD1 cDNA, as well as the genomic structure. It was determined to have six exons ( Fig. 2A) , identical to what is observed for the human and mouse genes. The exon-intron junctions were also shown to be conserved (Fig. 2B) . After sequencing of the 17bHSD1 gene, equine-specific primers were designed and used to amplify a RT-PCR product that extended the entire length of the cDNA open reading frame, thereby confirming that all RT-PCR products were derived from the same transcript ( Fig. 1A; RT-PCR2). The deduced 982 bp primary transcript encoded a 924 bp open reading frame ( Fig. 1A ; GenBank Accession number DQ418451), which predicted a protein of 308 amino acids.
The predicted protein is highly conserved when compared with human (NP_000404), marmoset (AAG01115), rat (AAH86365), and mouse (CAA61770) 17bHSD1 proteins (Fig. 3) . Equine 17bHSD1 has 73 . 3% identity at the amino acid level and 81 . 2% identity at the nucleic acid level relative to human 17bHSD1 (NM_000413). Homology was lost when the carboxy terminus of the proteins was examined and the proteins also exhibited variability in sizes; the equine 17bHSD1 is 20 amino acids shorter than human 17bHSD1, which is 16 amino acids shorter than both rodent proteins presented (Fig. 3) . The marmoset protein may be incomplete in its amino terminus. Figure 3 Equine 17bHSD1 predicted amino acid sequence. (A) The amino acid sequence of equine (equ) 17bHSD1 is aligned with the human (hum), marmostet (mar), rat, and mouse (mou) homologs. Identical residues are marked with a printed period, hyphens indicate gaps in protein sequences created to optimize alignment, and numbers on the right refer to the last amino acid on that line. The percentage presented at the end of each sequence represents the sequence's homology to the equine protein. hCG and in a placenta sample; whereas the message was very low or absent in all other tissues examined (Fig. 4A) . Abundance of the control gene rpL7a remained constant in all the tissues studied (Fig. 4B) .
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Regulation of 17bHSD1 mRNA in preovulatory follicles
The regulation of equine 17bHSD1 mRNA in preovulatory follicles isolated during estrus between 0 and 36 h after hCG treatment and in corpora lutea on day 8 of the estrous cycle was examined by RT-PCR/Southern blot. The results clearly demonstrated a dramatic decrease in 17bHSD1 transcript expression in equine follicles during the hCG-induced ovulatory/luteinization process. Elevated levels of 17bHSD1 mRNA were observed prior to hCG (0 h) with a pronounced downregulation observed 12 h post-hCG. Levels remained low, almost undetectable, in samples isolated between 24 and 36 h post-hCG, as well as in day 8 corpus luteum ( Fig. 5A) . No variation was observed in levels of rpL7a transcript in follicle wall and corpora lutea preparations (Fig. 5B) . When results from multiple follicles and corpora lutea were expressed as ratios of 17bHSD1 to rpL7a, a significant decrease in 17bHSD1 transcript was observed in follicles between 12 and 36 h after hCG treatment and in corpora lutea (P!0 . 05; Fig. 5C ).
In order to determine the contributions of the different steroidogenic cell types that make up the follicle wall, granulosa and theca interna cells were isolated from follicles obtained between 0 and 39 h after hCG treatment (Fig. 6) . The results revealed that the granulosa cell layer was the sole contributor of 17bHSD1 transcript expression. In this cell type, a significant decrease in 17bHSD1 mRNA was observed 12-39 h after hCG (P!0 . 05; Fig. 6A ). 17bHSD1 mRNA expression was low to absent in all theca interna samples examined (Fig. 6B ).
Binding activity of nuclear extract proteins to the 17bHSD1 proximal promoter Genomic cloning led to the characterization of a 1 . 4 kb fragment of 5 0 -flanking DNA region (Fig. 7) . Use of transcription start site prediction software (www.fruitfly. org/seq_tools/promoter.html) identified a putative transcription start site 23 bp upstream of the ATG start codon (Fig. 7) . Putative cis-acting elements located within 300 bp upstream of the transcription start site were identified with the TRANSFAC database (http:// motif.genome.jp/) and included a C/EBP, an AP-2, two GATA, an SF-1, a NFkB, two Sp1, and a cAMP response element (CRE) element. To determine whether hCG affected the binding of putative transcriptional regulators to the K230/K30 fragment (C1 representing the transcriptional start site) of the 17bHSD1 promoter, nuclear extracts from granulosa cells isolated from preovulatory follicles obtained at 0 and 30 h post-hCG were used in EMSA. Results demonstrated that a major protein/DNA complex was formed with nuclear extracts at 0 h post-hCG (Fig. 8A, lane 2) . The use of 30 h post-hCG nuclear extracts did not affect the migration of the band, but resulted in a net decrease in protein binding (Fig. 8A, lane 3) . To characterize the specificity of protein/DNA interactions, EMSAs were performed using molar excess of unlabeled oligonucleotides (Fig. 8D) containing various putative transcription factor-binding sites present within the K230/K30 fragment (Fig. 8A, lanes 4-7) . Results showed that competitors containing Sp1-binding sites reduced protein-promoter complex formation (Fig. 8A, lane 5) , whereas no effect was observed when competitors containing the first GATA or C/EBP and AP-2 elements were used (Fig. 8A, lanes 4 and 6) . Interestingly, the signal was completely abolished when an oligonucleotide contained both SF-1/NFkB and the second GATA binding sites was used as a competitor (Fig. 8A, lane 7) .
To further confirm the specificity of binding to the putative binding sites, individual transcription factorspecific regions were mutated and again used as competitors. The previously observed SF-1/NFkB/ GATA competition was greatly reduced when either sites were mutated, indicating a putative and collaborative binding instance (Fig. 8B, lanes 4 and 5) . To investigate the potential presence of NFkB, SF-1, and GATA protein in the binding complex, supershift EMSAs were performed using antibodies specific to the p50 and p65 subunits of NFkB, as well as antibodies specific for GATA-4 and equine SF-1. The intensity of the major band decreased when the anti-p65 antibody was used (Fig. 8B , lane 7 vs lane 2, band (a)), and a clear supershift band appeared when the anti-equine SF-1 antibody was used (Fig. 8C, lane 3 vs lane 2, band (b) ). No change in intensity was discernable when the antip50 or anti-GATA4 antibodies were used (Fig. 8B, lanes  6 and 8 vs lane 2, band (a) ). Figure 6 Cell type-dependent expression and regulation of 17bHSD1 mRNA in equine preovulatory follicles. RNA extracts were prepared from granulosa cells (A) and theca interna (B) isolated from equine preovulatory follicles between 0 and 39 h post-hCG, and samples (100 ng) were analyzed for 17bHSD1 and rpL7a by semi-quantitative RT-PCR/Southern blotting, as described in Materials and Methods. Autoradiograms show representative results of 17bHSD1 and rpL7a mRNA levels (one sample per time point). The 17bHSD1 signal was normalized with rpL7a, and results are presented as a ratio of 17bHSD1 to rpL7a (meanGS.E.M.; nZ4 samples (i.e. mares) per time point). Bars marked with an asterisk are Anti-equine SF-1 antibody specificity and expression of SF-1 protein in equine preovulatory follicles
The SF-1 antibody specificity and the hCG-dependent downregulation of the SF-1 protein were demonstrated at the protein level by immunoblot in follicles at 0 and 39 h post-hCG. As shown, the antibody raised in rabbit recognized the equine SF-1 protein from preovulatory follicle cell extracts, with two bands appearing at approximately 52 kDa (Fig. 8E) . Gonadotropin treatment resulted in a marked decrease in SF-1 protein expression (Fig. 8E) .
Discussion
This is the first study to identify hCG as a negative regulator of 17bHSD1 mRNA expression during the follicular luteinization in granulosa cells of a monoovulatory species. Follicular luteinization/ovulation has previously been associated with dramatic changes in steroidogenic enzyme expression. Enzymes responsible for androgen and estrogen biosynthesis have been shown to be downregulated, whereas the expression of those responsible for enhanced progesterone synthesis is upregulated (Fortune 1994 , Richards 1994 , Ronen--Fuhrmann et al. 1998 , Sandhoff et al. 1998 ). This study thereby provides an additional molecular basis for the decrease in 17b-estradiol production. Previous investigations of 17bHSD1 in the ovary have included its detection by northern blot in the rat (Ghersevich et al. 1994) , RT-PCR in humans (Nelson et al. 2001) , in situ hybridization, and Southern blotting in mice (Sha et al. 1997 , Pelletier et al. 2004 , as well as in human corpora lutea by immunohistochemistry (Vaskivuo et al. 2002) . It has been detected in the granulosa cells of developing follicles in immature and mature rats (Akinola et al. 1997) , and its regulation during the ovulatory process has been examined in rodents; however, it was limited by the use of immature hypophysectomized rats (Ghersevich et al. 1994) .
This study characterizes the hCG-dependent downregulation of 17bHSD1 transcript expression in a series of preovulatory follicles from a monoovulatory species. Previous reports using immature hypophysectomized rats have demonstrated that recombinant follicle stimulating hormone (FSH) had a stimulatory effect on 17bHSD1 transcript and protein expression, and that further treatment with hCG resulted in a downregulation of 17bHSD1 mRNA, visible after 1 day of treatment (Ghersevich et al. 1994 ). The present study shows that this downregulation is already visible 12 h after hCG treatment in the equine preovulatory follicle. Therefore, the results presented herein are consistent with the previous report and further establish the rapidity of 17bHSD1 transcript downregulation.
The molecular control of the 17bHSD1 gene in granulosa cells has remained largely uncharacterized. It has been shown, however, that AP-2 can interfere with Sp1 binding, and that GATA-3 can prevent transcription of constructs containing the 17bHSD1 proximal promoter in choriocarcinoma cells (Piao et al. 1997) . Further, retinoic acids and activin-A have been demonstrated to induce 17bHSD1 mRNA in human JEG-3 cells and cultured rat granulosa cells respectively (Piao et al. 1997 , Ghersevich et al. 2000 , Zhu et al. 2002 . The present study demonstrates for the first time the gonadotropin-dependent decrease in nuclear extract binding to the 17bHSD1 proximal promoter and identifies SF-1 and NFkB as putative cis-acting elements in 17bHSD1 transcriptional regulation. Interestingly, the transcript for SF-1 has previously been shown to be downregulated after hCG treatment in these same follicles (Boerboom et al. 2000) , thereby supporting the present observation of SF-1 protein downregulation after hCG. Moreover, the inverted SF-1-binding site identified in this study is identical to that reported for Figure 7 Isolation and characterization of the equine 17bHSD1 promoter. Numbering is relative to the putative transcription start site (C1) and the ATG translation start codon is in bold. The oligos used in competition assays are boxed. Putative cis-acting elements located within the 300 bp upstream of the start site are as follows: oligo 1, GATA (italic); oligo 2, Sp1 (italic); oligo 3, C/EBP (bold) and AP-2 (italic); and oligo 4, NFkB/SF-1 (bold) and GATA (italic). The probe used in binding assays is double underlined. The nucleotide sequence of the 1 . 4 kb promoter fragment is part of the genomic sequence deposited to GenBank (Accession number DQ418450).
the bovine CYP11A gene, encoding the cytochrome P450 side-chain cleavage enzyme, and this sequence has been demonstrated to bind the SF-1 protein (Liu & Simpson 1997) . Even though incubation of the anti-p65 NFkB antibody with the nuclear extract did not lead to the formation of an antibody-protein-DNA complex, it did lead to the displacement of binding of nuclear proteins to the oligonucleotide, and the level of displacement may in part be due to the antibody raised against the human protein. Nonetheless, the decrease in complex formation observed using this antibody is indicative that this transcription factor may be involved in promoter regulation. Interestingly, NFkB has been demonstrated to activate transcription of the CYP19A1 gene (Fan et al. 2005) . CYP19A1 encodes the cytochrome P450 enzyme aromatase, whose role in estrogen biosynthesis has largely been characterized (Simpson et al. 2005) . In that study, it was shown that the activation of NFkB resulted in an upregulation of CYP19A1's promoter II activity and that this may be due Figure 8 Gonadotropin-dependent regulation of DNA-binding activities in equine granulosa cell nuclear extracts. (A) Nuclear protein extracts were prepared from granulosa cells of follicles isolated before (0 h) and after (30 h) hCG treatment (lanes 2 and 3), as described in Materials and methods. Extracts were incubated with 32 P-labeled 17bHSD1 promoter fragment K230/K30, and protein-DNA interactions were studied by EMSAs. For reference purposes, the major protein-DNA complex is designated as band a. Competitive EMSAs were performed in the presence of various unlabeled competitor DNA (lanes 4-7). (B) Competitive EMSAs and supershift assays were performed in the presence of nuclear extracts prepared from granulosa cells from follicles isolated prior to hCG-treatment, 32 P-labeled oligo 4 and various unlabeled competitor wild-type and mutated DNA, as well as with NFkB and GATA-specific antibodies. (C) Supershift assay performed in the presence of nuclear extracts prepared from granulosa cells from follicles isolated prior to hCG-treatment, to the direct interaction of the p65 subunit of NFkB with the CYP19A1 promoter as identified by chromatin immunoprecipitation (Fan et al. 2005) . In addition, peroxisome proliferator-activated receptor-g and retinoid X receptor were speculated of downregulating aromatase expression, when stimulated simultaneously by disrupting the p65-promoter interaction (Mu et al. 2001 , Fan et al. 2005 . Considering that the regulation of CYP19A1, transcript levels of which are high in equine preovulatory follicles at 0 h and drop dramatically after hCG (Boerboom et al. 1999) , is identical to the regulation observed for 17bHSD1, further studies will be needed to unravel whether similar or distinct transcriptional mechanisms are involved.
The 17bHSD1 cDNA has previously been cloned in various species, including human (Peltoketo et al. 1988) , rat (Ghersevich et al. 1994) , and mouse (Nokelainen et al. 1996) . This study presents the equine cDNA and gene structure. Its genomic structure is consistent with that of other species, as they all have been demonstrated to have six exons and five introns. A pseudogene present upstream of the 17bHSD1 gene has been identified in humans, orang utan, chimpanzees, and gibbons; however, it is not conserved in all species (Keller et al. 2005 ). It will be interesting to determine if this is also the case in horses. In addition, the sizes of introns 3 and 4 vary slightly between species and the 3 0 end of exon 6 has been shown to exhibit considerable variability from one species to the next (Keller et al. 2005) , as is the case in the mare. This variability is discernable when examining the amino acid sequence of the carboxy terminus and the length of the 17bHSD1 proteins. A putative TATAbox motif was identified approximately 30 bp upstream of the transcription start site of the equine gene. An initiator (Inr) sequence ((C/T) 2 -C-A-(C/T) 5 ), located at the transcription start site, also appears to be present (Lewin 2000) . Notwithstanding, these sequences are not exact matches to traditional TATA and Inr sequences, and their relevance in transcriptional activation remains to be elucidated.
This study also investigates the expression of 17bHSD1 mRNA in equine tissues and establishes high levels of 17bHSD1 transcript in preovulatory follicles prior to hCG. While high levels of equine 17bHSD1 mRNA were also observed in a placenta sample, which is consistent with the high 17bHSD1 mRNA and protein observed in placentae of humans and non-human primates (Lin et al. 1992 , Castagnetta et al. 1997 , Schwabe et al. 2001 , this is not the case for rodents, however (Akinola et al. 1997) . It has also been detected by in situ hybridization in mice in granulosa cells of growing follicles, the intermediate lobe melanotrophs of the pituitary, in epithelial cells of the prostate, and in germ cells of the testis (Pelletier et al. 2004) . It is further found in the epithelium of normal and cancerous breast tissue of women by in situ hybridization (Soderqvist et al. 1998 , Miettinen et al. 1999 , Oduwole et al. 2004 .
In summary, this study is the first to characterize the primary structure of the equine 17bHSD1 cDNA and gene, to demonstrate the regulation of this gene during follicular luteinization in a monoovulatory species, to identify the preovulatory gonadotropin signal as a negative regulator of equine 17bHSD1 mRNA expression, and to propose NFkB and SF-1 as putative cis-acting elements in 17bHSD1 promoter activation. Considering the estrogen-activating activity of 17bHSD1, its gonadotropin-dependent downregulation provides an additional molecular basis for the decrease in 17b-estradiol biosynthetic capacity observed during the process of ovulation/luteinization.
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